MEI Pharma's $100M Litecoin Investment Sparks 111% Stock Surge, Second $100M Raise in Works

MEI Pharma (NASDAQ: MEIP) has become the first publicly traded company on a national exchange to allocate a significant portion of its treasury reserves to Litecoin (LTC). On July 18, 2025, the biopharmaceutical firm executed a $100 million private investment in public equity (PIPE) deal, issuing approximately 29.2 million shares at $3.42 apiece to fund the purchase of the cryptocurrency. This move has sparked a 111% surge in MEIP’s stock price over five days, reflecting heightened investor confidence in corporate adoption of digital assets [1]. The funding attracted notable institutional and industry stakeholders, including Litecoin’s creator Charlie Lee, crypto trading firm GSR, and the Litecoin Foundation, while entities like MOZAYYX, ParaFi, and HiveMind also participated. MEI Pharma’s board has added Lee as a member, leveraging his expertise to guide the company’s crypto strategy.

The company has engaged GSR as its digital asset and treasury management advisor, emphasizing a professional approach to managing its Litecoin holdings. MEIP’s stock closed at $6.86 on its most recent trading session, a 4.73% increase, though pre-market activity showed a 3.79% pullback. This volatility underscores the market’s mixed but generally positive reaction to MEI Pharma’s unconventional treasury strategy [1].

Litecoin’s price has risen 21.9% over the past week, reaching approximately $117.3 at the time of writing, aligning with MEI Pharma’s strategic timing. Technical analysts have highlighted the cryptocurrency’s potential breakout from a seven-year compression channel, describing its chart as “one of the most bullish looking in crypto right now” [1]. Crypto analyst Crypto Snorlax further noted Litecoin’s favorable risk/reward profile and liquidity, suggesting a 10x price increase could materialize during the ongoing bull cycle if ETF approvals and mid-altcoin seasonality play out.

MEI Pharma’s commitment to Litecoin has not ended with the initial $100 million investment. The company is reportedly preparing a second equity raise to amass an additional $100 million in LTC, signaling a total planned investment of $200 million. David Schwartz of the Litecoin Foundation confirmed the development, underscoring the firm’s conviction in the cryptocurrency’s long-term institutional viability [1]. This aggressive accumulation strategy positions MEI Pharma as a pioneer in bridging traditional corporate finance with the crypto ecosystem, a move analysts suggest could catalyze broader adoption across industries.

The stock surge and institutional backing highlight a growing trend of integrating digital assets into corporate treasuries. MEI Pharma’s initiative demonstrates how companies can leverage cryptocurrencies to diversify reserves, attract investor attention, and tap into speculative market dynamics. While Litecoin’s future performance remains subject to macroeconomic and regulatory factors, the surge in institutional interest—from strategic partnerships to technical analysis—reinforces its credibility as a hedge against traditional financial volatility.

Source: [1] [MEI Pharma’s $100 Million Litecoin Purchase Sparks Stock Surge Amid Growing Institutional Interest] [https://en.coinotag.com/mei-pharmas-100-million-litecoin-purchase-sparks-stock-surge-amid-growing-institutional-interest/]